Ventripoint Diagnostics Publishes Whitepaper on the Use of AI in Whole-Heart Analysis

(TheNewswire)

Toronto, Ontario – TheNewswire - March 24, 2025 -Ventripoint Diagnostics Ltd. (" Ventripoint " orthe " Company "), (TSXV:VPT; OTC:VPTDF) ispleased to announce the release of a whitepaper comparing theperformance of the VMS+™4.0 advanced Automated Radiological ImageProcessing Software/System to the previous basic model, VMS+ 3.0.

This latest advancement of Ventripoint’s proprietarytechnology, VMS+ 4.0 ,which recently received U.S. FDA 510(k) clearance, delivers a numberof significant enhancements including:

• AI-assisted automated point placement to improve userworkflow efficiency

• User tools to assist with analysis of the cardiacviews

• Enhanced visualization tools

• Measurements generated from the 3D wire mesh:

  • ED Volume,

  • ED Volume Index,

  • ES Volume,

  • ES Volume Index,

  • Ejection Fraction,

  • Cardiac Output,

  • Cardiac Index,

  • Stroke Volume,

  • Stroke Volume Index.

• Reporting of all measurements and derived parameters

The VMS+ system connects to standard echocardiographymachines, the most widely used cardiac imaging technology globally.The VMS+ 4.0 model usesconventional AI approaches to select anatomical landmarks fromstandard echocardiogram images which are then fed into Ventripoint’sproprietary Knowledge Based Reconstruction AI technology to create 3Dvisualizations of the heart and calculates volumes and ejectionfraction for all 4 cardiac chambers with accuracy equivalent to MRI. The combination of both AI engines allows for assisting automatedpoint-placement of the analysis with improved reliability andconfidence in the measurements.

“Ventripoint has deep experience in the applicationof AI to echocardiography and we have continued to invest in researchand development focused towards enhancing ease-of-use and integrationinto clinical workflow,” said Ventripoint President and CEO, HughMacNaught. “During the development process for VMS+™ 4.0 our teamworked with clinical collaborators to assess the performance ofautomated features, which is described in the whitepaper. It isessential that clinicians have confidence and trust in the results. The whitepaper illustrates the robustness and performance ofVMS+™. We are excited with the opportunity to offer hospitals anefficient and effective, non-invasive heart-imaging tool.  AIenhanced echocardiograms are a fast, affordableand accessible tool for diagnosis and monitoring of the growingnumbers of cardiac patients throughout the world.”

VMS+™ 4.0 has received regulatory clearance in keymarkets such as the U.S., E.U., U.K. and Canada making this latestversion of VMS+™ available to the global community.

The whitepaper can be viewed on the Ventripoint website www.ventripoint.com

About Ventripoint DiagnosticsLtd.

Ventripoint is an industry leader in the application ofAI (Artificial Intelligence) to echocardiography. Ventripoint'sVMS+™ products are powered by its proprietary Knowledge BasedReconstruction technology, which is the result of a decade ofdevelopment and provides accurate volumetric cardiac measurementsequivalent to MRI. This affordable, gold-standard alternative allowscardiologists greater confidence in the management of their patients.Providing better care to patients serves as a springboard and basicstandard for all of Ventripoint's products that guide our futuredevelopments. In addition, VMS+™ is versatile and can be used withall ultrasound systems from any vendor supported by regulatory marketapprovals in the U.S., Europe, and Canada.

For further information, please contact:

Hugh MacNaught

hmacnaught@ventripoint.com

604-671-4201

Forward Looking Statements

This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.

Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company's mostrecent annual management's discussion andanalysis that is available on the Company's profile on SEDAR atwww.sedar.com. Readers are cautioned that the foregoing list offactors is not exhaustive. The forward-looking statements included inthis news release are expressly qualified by this cautionarystatement. The forward-looking statements and information contained inthis news release are made as of the date hereof and the Companyundertakes no obligation to update publicly or revise anyforward-looking statements or information, whether as a result of newinformation, future events or otherwise, unless so required byapplicable securities laws.

Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.

Copyright (c) 2025 TheNewswire - All rights reserved.